Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Next Previous
Search
Trial Profile

A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanthanum carbonate (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Unicycive Therapeutics

Most Recent Events

  • 10 Apr 2025 According to Unicycive Therapeutics media release, data from this study will be presented today in poster sessions at the NKF Spring Clinical Meetings taking place in Boston on Thursday, April 10, from 5:15-7:30 p.m. ET.
  • 10 Apr 2025 Results presented in the Unicycive Therapeutics Media Release.
  • 12 Jun 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top